Human Genome Epidemiology Literature Finder
Records 1 - 19 (of 19 Records) |
Query Trace: Delayed Graft Function and CYP3A5[original query] |
---|
Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation 2008 Nov 86 (9): 1206-13. Bandur Stepan, Petrasek Jan, Hribova Petra, Novotna Eva, Brabcova Irena, Viklicky Ondr |
A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. Clinical therapeutics 2010 Nov 32 (12): 2012-23. Kuypers Dirk R J, de Jonge Hylke, Naesens Maarten, Vanrenterghem Yv |
CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2011 Sep 26 (9): 3046-50. Glowacki François, Lionet Arnaud, Buob David, Labalette Myriam, Allorge Delphine, Provôt François, Hazzan Marc, Noël Christian, Broly Franck, Cauffiez Christel |
Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. Therapeutic drug monitoring 2011 Apr 33 (2): 178-84. Bouamar Rachida, Hesselink Dennis A, van Schaik Ron H N, Weimar Willem, Macphee Iain A M, de Fijter Johan W, van Gelder Te |
Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Therapeutic drug monitoring 2014 Feb 36 (1): 71-9. Elens Laure, Hesselink Dennis A, Bouamar Rachida, Budde Klemens, de Fijter Johannes W, De Meyer Martine, Mourad Michel, Kuypers Dirk R J, Haufroid Vincent, van Gelder Teun, van Schaik Ron H |
CYP2C8*3 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors. Journal of clinical pharmacology 2013 Apr 53 (4): 427-34. Gervasini Guillermo, Garcia Montserrat, Macias Rosa María, Benitez Julio, Caravaca Francisco, Cubero Juan Jo |
Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients. Pharmacogenetics and genomics 2014 Dec 24 (12): 597-606. Kuypers Dirk R J, de Loor Henriette, Naesens Maarten, Coopmans Tamara, de Jonge Hyl |
Association of CYP3A variants with kidney transplant outcomes. Renal failure 2015 May 37 (4): 562-6. Traynor Carol, Conlon Peter, Phelan Paul J, O'Kelly Patrick, Elens Laure, McCormack Mark, Cavalleri Gianpiero, Comber Harry, van Schaik R H N, Conlon Peter |
Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients. Pharmacogenomics and personalized medicine 2017 10 101-106. Salgado Patricia C, Genvigir Fabiana Dv, Felipe Claudia R, Tedesco-Silva Helio, Medina-Pestana Jose O, Doi Sonia Q, Hirata Mario H, Hirata Rosario |
Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based Treatment in Brazilian Kidney Transplant Recipients. Pharmacotherapy 2017 Mar . Genvigir Fabiana D V, Nishikawa Alvaro M, R Felipe Claudia, Tedesco-Silva Helio, Oliveira Nagilla, Salazar Antony B C, Medina-Pestana Jose O, Doi Sonia Q, Hirata Mario H, Hirata Rosario D |
Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients. Clinical transplantation 2017 Nov . Asempa Tomefa E, Rebellato Lorita M, Hudson Suzanne, Briley Kimberly, Maldonado Angela |
Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenetics and genomics 2018 11 29 (1): 9-17. Hu Rong, Barratt Daniel T, Coller Janet K, Sallustio Benedetta C, Somogyi Andrew |
Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients. Iranian journal of kidney diseases 2019 Nov 13 (6): 414-416. Ghafari Somayeh, Dashti-Khavidaki Simin, Khatami Mohammad-Reza, Ghahremani Mohammad-Hossein, Seyednejad Seyed-Afshin, Beh-Pajooh Abb |
CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy. Pharmacogenomics 2019 12 21 (1): 7-21. Genvigir Fabiana Dalla Vecchia, Campos-Salazar Antony Brayan, Felipe Claudia Rosso, Tedesco-Silva Helio, Medina-Pestana José Osmar, Doi Sonia de Quateli, Cerda Alvaro, Hirata Mario Hiroyuki, Herrero María José, Aliño Salvador Francisco, Hirata Rosario Dominguez Cres |
The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center. Frontiers in genetics 2019 10 10 871. Abdel-Kahaar Emaad, Winter Stefan, Tremmel Roman, Schaeffeler Elke, Olbricht Christoph J, Wieland Eberhard, Schwab Matthias, Shipkova Maria, Jaeger Simon |
Clinical Impact of the Adaptation of Initial Tacrolimus Dosing to the CYP3A5 Genotype After Kidney Transplantation: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical pharmacokinetics 2021 3 60 (7): 877-885. Yang Hui, Sun Yiqi, Yu Xiaojia, Hu Xiaopeng, Wang Wei, Zhang Xiaodong, Liu Liho |
Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. British journal of clinical pharmacology 2021 3 87 (10): 3901-3909. Sallustio Benedetta C, Noll Benjamin D, Hu Rong, Barratt Daniel T, Tuke Jonathan, Coller Janet K, Russ Graeme R, Somogyi Andrew |
Donor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant Recipients. Annals of transplantation 2022 Jul 27 e936276. Warzyszy?ska Karola, Zawistowski Micha?, Karpeta Edyta, Ja?brzykowska Agnieszka, Kosieradzki Maci |
Tacrolimus CYP3A Single-Nucleotide Polymorphisms and Preformed T- and B-Cell Alloimmune Memory Improve Current Pretransplant Rejection-Risk Stratification in Kidney Transplantation. Frontiers in immunology 2022 13 869554. Crespo Elena, Vidal-Alabró Anna, Jouve Thomas, Fontova Pere, Stein Maik, Mocka Sonila, Meneghini Maria, Sefrin Anett, Hruba Petra, Gomà Montserrat, Torija Alba, Donadeu Laura, Favà Alex, Cruzado Josep M, Melilli Edoardo, Moreso Francesc, Viklicky Ondrej, Bemelman Frederike, Reinke Petra, Grinyó Josep, Lloberas Nuria, Bestard Ori |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: